Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Bausch + Lomb Corporation ( (BLCO) ) has issued an update.
On December 17, 2025, Bausch + Lomb Corporation announced the appointment of Eduardo C. Alfonso, MD, and Steven H. Collis to its board of directors, effective January 1, 2026. These appointments follow board changes announced in August 2025 and bring renowned expertise to the company, with Dr. Alfonso’s leadership in ophthalmology and Mr. Collis’s significant contributions to the pharmaceutical sector. The additions aim to strengthen Bausch + Lomb’s strategic direction and operations as it pursues growth opportunities across the eye health industry.
The most recent analyst rating on (BLCO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
Bausch + Lomb’s overall stock score is driven by strong technical indicators and positive strategic outlook from recent corporate events. However, financial performance and valuation concerns, particularly negative profitability and cash flow issues, weigh down the score.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation is a global eye health company committed to improving vision and quality of life worldwide. The company provides innovative solutions including contact lenses, prescription products, over-the-counter offerings, and surgical devices, focusing on advancing eye health through innovation and care.
Average Trading Volume: 490,047
Technical Sentiment Signal: Buy
Current Market Cap: $6.01B
Find detailed analytics on BLCO stock on TipRanks’ Stock Analysis page.